Amiodarone sales will expand through 2036, with synthetic API at 93.5% within the API type segment and oral solids at 78.0% of the dosage form category in 2026. The market was valued at USD 26.97 million in 2025 and is forecast to record a 2.83% CAGR between 2026 and 2036.